Influence of typical environments on quantum processes

We present the results of studying the influence of different environmental states on the coherence of quantum processes. We choose to discuss a simple model which describe two electronic reservoirs connected through tunneling via a resonant state. The model could, e.g., serve as an idealization of inelastic resonant tunneling through a double barrier structure. We develop Schwinger's closed time path formulation of non-equilibrium quantum statistical mechanics, and show that the influence of the environment on a coherent quantum process can be described by the value of a generating functional at a specific force value, thereby allowing for a unified discussion of destruction of phase coherence by various environmental states: thermal state, classical noise, time dependent classical field, and a coherent state. The model allows an extensive discussion of the influence of dissipation on the coherent quantum process, and expressions for the transmission coefficient are obtained in the possible limits.Comment: 46 pages, 11 post script figures. Accepted for publication in Physical Review

The N∗(1710)N^*(1710) as a resonance in the ππN\pi\pi N system

We study the $\pi \pi N$ system by solving the Faddeev equations, for which the input two-body $t$-matrices are obtained by solving the Bethe-Salpeter equation in the coupled channel formalism. The potentials for the $\pi \pi$, $\pi N$ sub-systems and their coupled channels are obtained from chiral Lagrangians, which have been earlier used to study resonances in these systems successfully. In this work, we find a resonance in the $\pi\pi N$ system with a mass of $1704 - i 375/2$ MeV and with quantum numbers $I=1/2$, $J^\pi =1/2^+$. We identify this state with the $N^*(1710)$. This peak is found where the energies of the $\pi \pi$ sub-system fall in the region of the $\sigma$ resonance. We do not find evidence for the Roper resonance in our study indicating a more complex structure for this resonance, nor for any state with total isospin $I=3/2$ or $5/2$

Magnetic moments of the low-lying {1/2}^- octet baryon resonances

The magnetic moments of the negative parity octet resonances with spin {1/2}: $N^*$(1535), $N^*$(1650), $\Sigma^*$(1620), and $\Xi^*$(1690) have been calculated within the framework of the chiral constituent quark model. In this approach, the presence of the polarized $q\bar{q}$ pairs (or the meson cloud, in other words) is considered by using the Lagrangian for Goldstone boson emission from the constituent quarks. Further, the explicit contributions coming from the spin and orbital angular momentum, including the effects of the configurations mixing between the states with different spins, are obtained. The motivation for these calculations comes from the recent interest in experimental measurement of the magnetic moment of the ${S_{11}(1535)}$ resonance and of similar calculations being done within lattice quantum chromodynamics approaches. Our results can be compared with those expected to come from these sources.Comment: 17 pages, 2 table

Search for resonances in the mass distribution of jet pairs with one or two jets identified as b-jets in proton–proton collisions at √s=13TeV with the ATLAS detector

Searches for high-mass resonances in the dijet invariant mass spectrum with one or two jets identi-fied as b-jets are performed using an integrated luminosity of 3.2fb−1of proton–proton collisions with a centre-of-mass energy of √s=13TeVrecorded by the ATLAS detector at the Large Hadron Collider. Noevidence of anomalous phenomena is observed in the data, which are used to exclude, at 95%credibility level, excited b∗quarks with masses from 1.1TeVto 2.1TeVand leptophobic Z bosons with masses from 1.1TeVto 1.5TeV. Contributions of a Gaussian signal shape with effective cross sections ranging from approximately 0.4 to 0.001pb are also excluded in the mass range 1.5–5.0TeV

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Dichlorido(N,N '-dibenzylideneethane-1,2-diamine-kappa N-2,N ') (2,2-dimethyl-1,3-dioxolane-4,5-diyl)bis(diphenylmethan-olato)-kappa O-2,O ' titanium(IV)

The title compound, [TiCl2(C31H28O4)(C16H16N2)], is a titanium(IV) complex of the bidentate 2,2-dimethyl-, alpha,alpha,alpha ',alpha '-tetraphenyl-1,3-dioxolane-4,5-dimethanolate (TAD-DOLate) ligand containing also two chloride ions and a bidentate neutral N,N '-dibenzylideneethane-1,2-diamine ligand. The molecular structure has a distorted octahedral geometry around the titanium metal center. The Ti-N bond lengths of 2.246 ( 2) and 2.2476 ( 17) angstrom are long, indicating weak bonding between the titanium( IV) metal center and the imine N atoms. Though the two chloride ligands are trans to each other, they bend away from the Ti-TADDOLate bonds with a Cl-Ti-Cl angle of 163.96 ( 3)degree

Magnetic-field-dependent energy levels in a highly anisotropic electronic material

Contains fulltext : 112818.pdf (publisher's version ) (Open Access